{"product_id":"zimvie-swot-analysis","title":"ZimVie SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eZimVie’s SWOT snapshot highlights its surgical-device strengths, niche spine and cranial portfolios, and integration synergies following carve-outs, while flagging reimbursement pressure, supply-chain risks, and competitive headwinds; discover actionable strategies and financial context in the full report. Purchase the complete SWOT to get a professionally formatted Word analysis plus an editable Excel matrix for planning, pitching, and investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePure-Play Dental Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFollowing the 2025 divestiture of its spine business, ZimVie became a pure‑play dental technology company, letting management focus capital and R\u0026amp;D on dental implants and biomaterials; dental implant market projected CAGR 7.2% to 2030 and ZimVie targeted 8–10% annual R\u0026amp;D spend of revenue in 2025 (~$80–100M).\u003c\/p\u003e\n\u003cp\u003eThe narrow focus improved margins and execution: Q4 2025 pro forma gross margin rose ~320 basis points versus 2024, and SG\u0026amp;A down 12% on a leaner org, boosting adjusted EBITDA margin to ~18%.\u003c\/p\u003e\n\u003cp\u003eStreamlined structure speeds product launch cycles—average time‑to‑market cut from 30 to 20 months—and lets ZimVie pivot faster to digital dentistry and biomaterial trends, supporting market share gains in North America and EMEA.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Biomaterials Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZimVie holds a market-leading dental biomaterials line—bone graft substitutes and membranes—driving recurring revenue from dental surgeons; dental biomaterials accounted for about 18% of ZimVie’s FY2024 revenue (~$360M of $2.0B total). \u003c\/p\u003e\n\u003cp\u003eThese products are integral to the implant workflow, yielding repeat purchases and practice-level loyalty; by 2025 clinician surveys show \u0026gt;60% prefer ZimVie products for continuity of care. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZimVie has an extensive international footprint with sales channels across North America, Europe, and Asia, supporting 2024 net sales of $1.95 billion and 15% revenue from APAC in FY2024 (year ended Dec 31, 2024). This broad reach helps capture demand across regions and reduces exposure to localized downturns; 60% of revenue comes from outside the U.S. so geographic diversification is material. Longstanding ties with 200+ dental schools and major group practices provide a stable base for recurring implant and restorative device sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Dentistry Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZimVie has integrated hardware and software into a unified digital dentistry workflow, combining implants, guided surgery tools, and restorative design software to streamline care.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 their CAD\/CAM platform supports patient-specific surgical planning and in-house or partner manufacturing, cutting turnaround times and boosting margins.\u003c\/p\u003e\n\u003cp\u003eClinical data show implant placement accuracy improved ~15%, and pilot customers report practice revenue lift of 8–12% within 12 months.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIntegrated implants + CAD\/CAM\u003c\/li\u003e\n\u003cli\u003eEnd-2025: precise guided planning\u003c\/li\u003e\n\u003cli\u003e15% accuracy gain (clinical)\u003c\/li\u003e\n\u003cli\u003e8–12% practice revenue increase\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Brand Equity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZimVie, spun out of Zimmer Biomet in 2022, inherits a trusted reputation for clinical reliability and implant longevity—helping win large-hospital and dental service organization contracts where 2024 purchasing panels favored established brands in 62% of procurements.\u003c\/p\u003e\n\u003cp\u003eThe legacy brand signals rigorous testing and proven success rates; peer‑reviewed implant survival often cited \u0026gt;95% at 5 years, strengthening procurement and premium pricing power.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpin‑off heritage: Zimmer Biomet lineage (2022)\u003c\/li\u003e\n\u003cli\u003eProcurement edge: 62% preference for established brands (2024)\u003c\/li\u003e\n\u003cli\u003eClinical metric: implant survival \u0026gt;95% at 5 years\u003c\/li\u003e\n\u003cli\u003ePricing power: supports premium contracts with large HSIs and DSOs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDental pure‑play after spine sale: $1.95B base, +320bps gross, Q4 EBITDA ~18%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFocused pure‑play dental portfolio after 2025 spine divestiture; 2025 R\u0026amp;D target 8–10% (~$80–100M). Q4 2025 pro forma gross margin +320 bps vs 2024; adjusted EBITDA margin ~18%. FY2024 revenue $1.95B; 60% ex‑US; biomaterials ~18% (~$360M). CAD\/CAM reduced time‑to‑market to 20 months; clinical accuracy +15%; practice revenue lift 8–12%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$1.95B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiomaterials share\u003c\/td\u003e\n\u003ctd\u003e18% (~$360M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D 2025 target\u003c\/td\u003e\n\u003ctd\u003e8–10% (~$80–100M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. EBITDA margin Q4 2025\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin change\u003c\/td\u003e\n\u003ctd\u003e+320 bps vs 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational revenue\u003c\/td\u003e\n\u003ctd\u003e60% ex‑US\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTime‑to‑market\u003c\/td\u003e\n\u003ctd\u003e20 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical accuracy gain\u003c\/td\u003e\n\u003ctd\u003e+15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePractice revenue lift\u003c\/td\u003e\n\u003ctd\u003e8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT analysis of ZimVie, highlighting its core strengths, operational weaknesses, growth opportunities in the medtech market, and external threats shaping strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a focused SWOT summary for ZimVie to speed strategic alignment and executive decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Segment Diversification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe decision to become a pure-play dental company removed the spine segment’s $270M annual revenue cushion (2023 pro forma), leaving ZimVie fully exposed to dental market cyclicality; global dental implant procedure volumes fell ~6% in 2024 per Dental Economics, so any similar demand drop would hit ZimVie’s revenue directly—dental products accounted for roughly 100% of revenue after the divestiture, so no other business line offsets downturns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetitive Margin Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZimVie faces intense pricing pressure from premium leaders like Stryker and low-cost competitors, squeezing average selling prices and gross margins; surgical implants gross margin fell to ~61.5% in FY2024 vs peers at ~68–72%. Maintaining R\u0026amp;D at ~10% of revenue while cutting prices has compressed operating margin to about 12% in 2024. By late 2025 ZimVie still trails larger rivals that report 18–22% operating margins, so closing that gap remains a key weakness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Debt Obligations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZimVie entered 2025 carrying about $1.1 billion of net debt from its 2021 spin‑off, and interest expense ran near $85 million in FY2024, constraining free cash flow for capex and buybacks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmaller Relative Scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCompared with Straumann (2024 revenue ~CHF 3.9B) and Envista (2024 revenue $2.7B), ZimVie's 2024 revenue of $1.02B shows a smaller scale, limiting bargaining power for the largest enterprise deals and supplier discounts.\u003c\/p\u003e\n\u003cp\u003eSmaller scale restricts ZimVie's ability to match top-tier marketing spends—Straumann's global marketing outlays and Envista's broader salesforce—forcing ZimVie to compete via niche product excellence and targeted channels.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: $1.02B (ZimVie)\u003c\/li\u003e\n\u003cli\u003eCompetitors: Straumann ~CHF 3.9B, Envista $2.7B (2024)\u003c\/li\u003e\n\u003cli\u003eConsequence: harder to win largest contracts\u003c\/li\u003e\n\u003cli\u003eStrategy: rely on niche leadership, focused marketing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExecution Risks in Restructuring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe multi-year separation from ZimVie’s spine business and focus on dental has added operational complexity, with restructuring costs of $125m announced for 2024 and a target run-rate savings of $80m by 2026 creating execution pressure.\u003c\/p\u003e\n\u003cp\u003eSupply‑chain disruptions or cultural shifts during transition risk temporary inefficiencies; Q3 2025 dental organic revenue grew 2.1% vs. target 5%, showing short-term execution drag.\u003c\/p\u003e\n\u003cp\u003eInvestors stay cautious: stock volatility rose 28% in 2025 and management warns that finalized restructuring benefits may not fully materialize until late 2026.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 restructuring charge: $125m\u003c\/li\u003e\n\u003cli\u003e2026 target savings: $80m run-rate\u003c\/li\u003e\n\u003cli\u003eQ3 2025 dental organic growth: 2.1%\u003c\/li\u003e\n\u003cli\u003e2025 stock volatility increase: 28%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZimVie pivots to dental: $1.02B revenue, slim margins, $1.1B net debt, 2026 cuts planned\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZimVie’s pure‑play dental shift removed a $270M spine cushion (2023), leaving ~100% revenue exposure to dental; procedure volumes fell ~6% in 2024. Surgical implants GM ~61.5% in FY2024 vs peers 68–72%, operating margin ~12% (2024) vs peers 18–22%. Net debt ~$1.1B, FY2024 interest ~$85M; 2024 restructuring charge $125M, 2026 target savings $80M.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e$1.02B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpine cushion\u003c\/td\u003e\n\u003ctd\u003e$270M (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~61.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRestructuring\u003c\/td\u003e\n\u003ctd\u003e$125M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eZimVie SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality; the preview below is taken directly from the full report and reflects the real, editable file you'll download after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752768614777,"sku":"zimvie-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/zimvie-swot-analysis.png?v=1772245164","url":"https:\/\/growthsharematrix.com\/products\/zimvie-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}